(Q51063904)

English

Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).

scientific article published on 10 August 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

methicillin-resistant Staphylococcus aureus

0 references

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

Rong-mei Liang

1

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Xiao-lan Yong

2

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Yu-qin Duan

3

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Yong-hong Tan

4

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Ping Zeng

5

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Zi-ying Zhou

6

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Yan Jiang

7

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Shi-hua Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Yun-ping Jiang

9

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Xiao-chun Huang

10

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Zhao-hui Dong

11

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Ting-ting Hu

12

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Hui-qing Shi

13

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Nan Li

14

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

publication date

10 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

World Journal of Microbiology and Biotechnology

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

30

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

11

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

2861-2869

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Fusidic acid adverse drug reactions

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Berberine synergy with amphotericin B against disseminated candidiasis in mice

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Limitations of vancomycin in the management of resistant staphylococcal infections

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Vancomycin: a 50-year reassessment

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Resistance to fusidic acid.

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS11274-014-1712-2

21 January 2018

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

1 reference

https://pubmed.ncbi.nlm.nih.gov/25108628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence

1 reference

https://pubmed.ncbi.nlm.nih.gov/25108628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25108628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains

1 reference

https://pubmed.ncbi.nlm.nih.gov/25108628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibiotics--an investment worth making?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25108628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11274-014-1712-2

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25108628

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51063904&oldid=2210677121"